Circulating sgp130 levels have also been found to be increased in people with steatotic liver disease and steatohepatitis (metabolic dysfunction–associated steatotic liver disease (MASLD)/metabolic dysfunction–associated steatohepatitis (MASH)), and further increased in diabetes concurrent with steatohepatitis, with clear correlations between HbA1c and sgp130 levels in obesity.27 This evidence concerns the gene IL6ST and diabetes mellitus.